Compare SMHI & SLGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SMHI | SLGL |
|---|---|---|
| Founded | 1989 | 1997 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 207.0M | 247.1M |
| IPO Year | 2016 | 2016 |
| Metric | SMHI | SLGL |
|---|---|---|
| Price | $7.70 | $71.07 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $110.00 |
| AVG Volume (30 Days) | ★ 73.8K | 22.9K |
| Earning Date | 04-29-2026 | 05-22-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 62.41 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $173,783,000.00 | N/A |
| Revenue This Year | $1.21 | N/A |
| Revenue Next Year | $9.31 | $223.84 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.70 | $6.80 |
| 52 Week High | $8.17 | $97.97 |
| Indicator | SMHI | SLGL |
|---|---|---|
| Relative Strength Index (RSI) | 57.79 | 50.91 |
| Support Level | $6.91 | $66.48 |
| Resistance Level | $7.90 | $81.66 |
| Average True Range (ATR) | 0.33 | 6.82 |
| MACD | 0.04 | 0.74 |
| Stochastic Oscillator | 72.00 | 55.18 |
Seacor Marine Holdings Inc provides marine and support transportation services to offshore energy facilities globally. The company operates and manages a diverse fleet of offshore support vessels that (i) deliver cargo and personnel to offshore installations, including offshore wind farms, (ii) assist offshore operations for production and storage facilities, (iii) provide construction, well work-over, offshore wind farm installation and decommissioning support and (iv) carry and launch equipment used underwater in drilling and well installation, maintenance, inspection and repair. Its geographical segment includes the United States (Gulf of Mexico), Africa and Europe, Middle East and Asia, and Latin America, with the majority of revenue deriving from the Africa and Europe segment.
Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline includes SGT-610 (Patidegib Gel 2%), a new chemical entity hedgehog signaling pathway blocker, for the chronic use and prevention of new BCC in Gorlin syndrome patients, and the topical drug candidate SGT-210 for the treatment of Darier Disease and other rare keratosis-related indications such as PC, PPK and Olmsted.